Major developments span artificial cell biology breakthroughs, regulatory actions on drugs and tech platforms, NASA's rocket readiness challenges, and significant shifts in AI policy and EV technology.

Artificial cell successfully completes multiple rounds of cell division, marking a significant advance in synthetic biology and our understanding of fundamental cellular processes.

Africa CDC confirms Marburg virus case in Uganda amid ongoing Ebola outbreak, raising regional health emergency concerns and prompting disease surveillance efforts.

DEA plans to temporarily schedule kratom compound 7-OH as a controlled substance, responding to concerns about the opioid-like substance marketed as 'gas station heroin' while benefiting mainstream kratom industry players.

NASA faces delays in delivering critical rockets needed for space missions, with program readiness remaining uncertain despite agency's urgent requirements.

Trump administration secures only 5% OpenAI stake for the US, significantly lower than Senator Sanders' original proposal, raising questions about government influence in AI development.

Google loses lengthy EU antitrust appeal and must pay $4.7 billion fine for anti-competitive practices, concluding a major regulatory battle with European authorities.

Musk's X platform faces federal scrutiny from FTC over alleged serious privacy risks to Americans, adding to mounting regulatory pressure on the social media company.

EV manufacturer Slate adopts Chinese-perfected battery technology for cheaper vehicles, driven partly by Trump's repeal of domestic-sourcing EV tax credit requirements.

Meta introduces subscription model for advanced smart glasses features, signaling shift toward recurring revenue streams for consumer hardware devices.